Recent Quotes (30 days)

You have no recent quotes
chg | %

Cynapsus Therapeutics Inc  

(Public, CVE:CTH)   Watch this stock  
Find more results for CTH
Nov 27 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.38 - 1.51
Open     -
Vol / Avg. 0.00/303,419.00
Mkt cap 98.66M
P/E     -
Div/yield     -
EPS -0.14
Shares 79.56M
Beta 0.81
Inst. own     -
Aug 12, 2016
Q2 2016 Cynapsus Therapeutics Inc Earnings Release (Estimated) Add to calendar
Jul 19, 2016
Cynapsus Therapeutics Inc Analyst and Investor Day
May 12, 2016
Cynapsus Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference
May 11, 2016
Q1 2016 Cynapsus Therapeutics Inc Earnings Release
May 4, 2016
Cynapsus Therapeutics Inc at Deutsche Bank Health Care Conference

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -45.54% -46.11%
Return on average equity -47.97% -49.53%
Employees 25 -
CDP Score - -


828 Richmond St W
+1-416-7032449 (Phone)
+1-416-7038752 (Fax)

Website links


Cynapsus Therapeutics Inc. is a specialty central nervous system (CNS) pharmaceutical company. The Company is developing and preparing a sublingual thin filmstrip for the on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD). The Company operates in the research, development and commercialization of a sublingual film for the on-demand management of symptoms associated with PD segment. Its drug candidate, APL-130277, is a sublingual formulation of apomorphine hydrochloride, or apomorphine. The Company's APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine. Its APL-130277 is designed to convert all types of OFF episodes, including morning OFF episodes. The Company has initiated its Phase III clinical program for APL-130277. Cynapsus Therapeutics (USA) Inc. is the subsidiary of the Company.

Officers and directors

Rochelle E. Stenzler Independent Chairman of the Board
Age: 52
Anthony Giovinazzo President, Chief Executive Officer, Director
Andrew Williams Chief Financial Officer, Chief Operating Officer
Thierry Bilbault Executive Vice President - Chemistry, Manufacturing and Controls, Chief Scientific Officer
Kristen Galfetti Vice President of Investor Relations and Corporate Communications
Jordan Dubow M.D. Vice President - Medical Affairs
Albert Agro Chief Medical Officer
Frederick W. Driscoll Independent Director
Age: 65
Tomer Gold Independent Director
Ronald G. Hosking Independent Director
Age: 70